A client has been started on a drug that is an inhibitor of CYP3A4 enzymes. How could this affect the client's drug therapy?

A. This is a contraindication, and the drug should be stopped: Being prescribed a CYP3A4 inhibitor is not automatically a contraindication. While it may affect the metabolism of other drugs, it can often be managed by monitoring drug levels, adjusting dosages, or selecting alternative medications. B. Metabolism of other drugs may be slowed down: CYP3A4 is a major hepatic enzyme responsible for metabolizing many medications. Inhibition of this enzyme can reduce the metabolic clearance of co-administered drugs, leading to increased plasma concentrations, prolonged half-life, and a higher risk of adverse effects or toxicity. C. More drug will become bound to plasma proteins: Protein binding is determined by the drug’s affinity for plasma proteins and is largely independent of CYP enzyme activity. CYP3A4 inhibition affects drug metabolism rather than protein binding, so this mechanism does not explain changes in drug levels caused by enzyme inhibition. D. The client's creatinine clearance will decrease: Creatinine clearance reflects renal function and is not directly affected by CYP3A4 activity. While drug accumulation may occur with impaired metabolism, the enzyme inhibition itself does not alter kidney filtration or excretion rates.